October 06, 2018
2 min read

International cardiometabolic conference features ‘tomorrow’s clinical science’

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease provides an opportunity for clinical and basic scientists, researchers and practicing clinicians to collaborate on new data, emerging scientific principles and management strategies.

The World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) will hold its 16th annual conference Nov. 29 to Dec. 1 at the Universal City Hilton in Los Angeles. The international meeting is dedicated to diabetes, obesity, lipids, CVD, metabolism and energy balance, and links research to clinical practice. The theme of the 2018 meeting is “Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.”

Since its inception, the WCIRDC has brought researchers, clinicians, journalists and thought leaders together for an international program that explores the integration of new science into the development and application of new therapies, with a bench-to-bedside approach. Attendees can interact with a faculty of distinguished global experts. Working together, experts and clinicians further the understanding of metabolic diseases and translate new knowledge into best practices for using medications, devices and procedures to manage CVD and other complications, according to a press release.

This year, the congress will celebrate the life and scientific contributions of Gerald Reaven, MD, with a special session dedicated to his work, titled “The Metabolic Syndrome Revisited: A Salute to Gerald Reaven, MD.” This session will be chaired by Ralph A. DeFronzo, MD, and will feature lectures on the mechanisms, physiology and pathophysiology of insulin resistance, delivered by Peter Reaven, MD, and George King, MD, as well as DeFronzo, according to the release.

The congress will also honor the leadership and scientific work of Philipp E. Scherer, PhD, recipient of the newly named Gerald M. Reaven Distinguished Leader in Insulin Resistance Award, for his contribution to the development and understanding of the science and research of insulin resistance and diabetes. Scherer, a professor in the department of internal medicine at University of Texas Southwestern Medical Center and director of Touchstone Diabetes Center in Dallas, will deliver the keynote lecture, “The Central Role of Adipose Tissue for Metabolic Homeostasis and Systemic Insulin Sensitivity,” according to the release.

For specialists and primary care clinicians, the WCIRCD will also feature a series of workshops and “meet the expert” panels, which will address the clinical management of kidney disease, diabetes, obesity, lipids, high-risk CVD and more. Recognized clinical experts will provide special commentaries on the clinical practice implications of research into metabolism, vascular biology, obesity and diabetes.


The congress will also showcase state-of-the-art abstracts, which will be published in Endocrine Practice.

The congress promotes personal direct contact between the audience and the distinguished faculty, according to the release. The WCIRDC offers a reduced fee for readers/members by using code MEDIA30 when they register at www.wcir.org/registration. Up to 27 CME credits are offered, according to the release.

For more information :

Agenda and faculty list for WCIRDC are available at www.wcir.org.